Sintx Technologies (NASDAQ:SINT – Get Free Report) and Anika Therapeutics (NASDAQ:ANIK – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.
Valuation and Earnings
This table compares Sintx Technologies and Anika Therapeutics’ revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sintx Technologies | $2.63 million | 1.18 | -$8.26 million | ($358.00) | -0.01 |
| Anika Therapeutics | $166.66 million | 2.38 | -$82.67 million | ($5.25) | -5.19 |
Sintx Technologies has higher earnings, but lower revenue than Anika Therapeutics. Anika Therapeutics is trading at a lower price-to-earnings ratio than Sintx Technologies, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sintx Technologies | 0 | 1 | 0 | 0 | 2.00 |
| Anika Therapeutics | 0 | 1 | 1 | 0 | 2.50 |
Anika Therapeutics has a consensus target price of $30.50, suggesting a potential upside of 11.60%. Given Anika Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Anika Therapeutics is more favorable than Sintx Technologies.
Profitability
This table compares Sintx Technologies and Anika Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sintx Technologies | -318.99% | -81.96% | -52.43% |
| Anika Therapeutics | -45.39% | 0.48% | 0.39% |
Institutional and Insider Ownership
18.4% of Sintx Technologies shares are held by institutional investors. Comparatively, 91.5% of Anika Therapeutics shares are held by institutional investors. 1.0% of Sintx Technologies shares are held by company insiders. Comparatively, 7.9% of Anika Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Volatility and Risk
Sintx Technologies has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500. Comparatively, Anika Therapeutics has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.
Summary
Anika Therapeutics beats Sintx Technologies on 11 of the 13 factors compared between the two stocks.
About Sintx Technologies
Sintx Technologies, Inc., an advanced ceramics company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, technical, and antipathogenic applications in the United States. It provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials, polyetheretherketone, and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah.
About Anika Therapeutics
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
Receive News & Ratings for Sintx Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sintx Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
